Show simple item record

dc.contributor.authorHanna, C
dc.contributor.authorKurian, KM
dc.contributor.authorWilliams, K
dc.contributor.authorWatts, C
dc.contributor.authorJackson, A
dc.contributor.authorCarruthers, R
dc.contributor.authorStrathdee, K
dc.contributor.authorCruickshank, G
dc.contributor.authorDunn, L
dc.contributor.authorErridge, S
dc.contributor.authorGodfrey, L
dc.contributor.authorJefferies, S
dc.contributor.authorMcBain, Catherine A
dc.contributor.authorSleigh, R
dc.contributor.authorMcCormick, A
dc.contributor.authorPittman, M
dc.contributor.authorHalford, S
dc.contributor.authorChalmers, AJ
dc.date.accessioned2020-06-15T12:57:37Z
dc.date.available2020-06-15T12:57:37Z
dc.date.issued2020en
dc.identifier.citationHanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, et al. Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020.en
dc.identifier.pmid32347934en
dc.identifier.doi10.1093/neuonc/noaa104en
dc.identifier.urihttp://hdl.handle.net/10541/622964
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1093/neuonc/noaa104en
dc.titlePharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trialen
dc.typeArticleen
dc.contributor.departmentInstitute of Cancer Sciences, University of Glasgow, United Kingdom.en
dc.identifier.journalNeuro-Oncologyen
dc.description.noteen]
refterms.dateFOA2020-06-22T11:33:07Z


Files in this item

Thumbnail
Name:
noaa104.pdf
Size:
1.121Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record